Sales of first big COVID-19 drug, remdesivir, may disappoint

LONDON: Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc. reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first ...

from Google Alert - Business https://ift.tt/3nVDEzU
LONDON: Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc. reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first ... https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize